Cargando…
1612P Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
Autores principales: | Guven, D.C.C., Gulbahce Incesu, F.G., Yildirim, H.C., Erul, E., Chalabiyev, E., Aktas, B.Y., Yuce, D., Arik, Z., Kilickap, S., Aksoy, S., Erman, M., Hayran, K.M., Unal, S., Alp, A., Dizdar, O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472463/ http://dx.doi.org/10.1016/j.annonc.2022.07.1705 |
Ejemplares similares
-
1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days
por: Aktas, B.Y., et al.
Publicado: (2020) -
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis
por: Guven, Deniz Can, et al.
Publicado: (2022) -
Evaluation of cancer risk in patients with periodontal diseases
por: GÜVEN, Deniz Can, et al.
Publicado: (2019) -
Reproductive cancer risk factors among relatives of cancer patients in a tertiary oncology center
por: Atta, Nooria, et al.
Publicado: (2019) -
1724P Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients
por: Guven, D.C., et al.
Publicado: (2020)